arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2007-13-1-27-29arthyper-1102Research ArticleЛЕКЦИЯ ДЛЯ ВРАЧЕЙРоль антагонистов кальция
в лечении пациентов с сочетанием артериальной
гипертензии и ИБСThe role of calcium anataginists
in the treatment of hypertensive patients with
coronary artery diseaseКарповЮ. А.KarpovYu. A.noemail@neicon.ruФГУ РКНПК РосздраваРоссия2007280220071312729Copyright © Карпов Ю.А., 20072007Карпов Ю.А.Karpov Y.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/1102ReferencesArmstrong P.W. Stable ischemic syndromes. In: Textbook of cardiovascular medicine. Ed. Topol E.J. Philadelphia, P.A., Lippincott Williams & Wilkins- Raven; 1998: 333-364.Armstrong P.W. Stable ischemic syndromes. In: Textbook of cardiovascular medicine. Ed. Topol E.J. Philadelphia, P.A., Lippincott Williams & Wilkins- Raven; 1998: 333-364.Под редакцией акад. Е.И.Чазова. Болезни сердца и сосудов. Руководство для врачей. В 4 томах. Москва, Медицина, 1992. Том 2, с. 5-42.Под редакцией акад. Е.И.Чазова. Болезни сердца и сосудов. Руководство для врачей. В 4 томах. Москва, Медицина, 1992. Том 2, с. 5-42.Neaton J.D.,Wentworth D., for the Multiple Risk Factor Intervention Trial Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316,099 white men. Arch Intern Med 1992; 152; 56-64.Neaton J.D.,Wentworth D., for the Multiple Risk Factor Intervention Trial Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316,099 white men. Arch Intern Med 1992; 152; 56-64.Collins R., Peto R., MacMahon S., et al. Blood pressure, stroke, and coronary heart disease. Part 2: Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.Collins R., Peto R., MacMahon S., et al. Blood pressure, stroke, and coronary heart disease. Part 2: Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.Карпов Ю.А. Ишемическая болезнь сердца в сочетании с артериальной гипертонией: особенности течения и лечения. Руководство по артериальной гипертонии/Под редакцией академика Е.И. Чазова, профессора И.Е. Чазовой. - М.: Медиа Медика, 2005;434-453.Карпов Ю.А. Ишемическая болезнь сердца в сочетании с артериальной гипертонией: особенности течения и лечения. Руководство по артериальной гипертонии/Под редакцией академика Е.И. Чазова, профессора И.Е. Чазовой. - М.: Медиа Медика, 2005;434-453.Карпов Ю.А., Шальнова С.А., Деев А.Д., от имени участников программы ПРЕМЬЕРА. Престариум у больных с артериальной гипертонией и ишемической болезнью сердца (или факторами риска) - безопасное достижение целевого уровня артериального давления (ПРЕМЬЕРА): результаты клинического этапа национальной программы. Кардиология 2006; 6: 32-38.Карпов Ю.А., Шальнова С.А., Деев А.Д., от имени участников программы ПРЕМЬЕРА. Престариум у больных с артериальной гипертонией и ишемической болезнью сердца (или факторами риска) - безопасное достижение целевого уровня артериального давления (ПРЕМЬЕРА): результаты клинического этапа национальной программы. Кардиология 2006; 6: 32-38.Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension 2003; 21: 1011-1053.Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension 2003; 21: 1011-1053.Всероссийское научное общество кардиологов (ВНОК). Национальные рекомендации по диагностике и лечению артериальной гипертонии. М., 2004г.Всероссийское научное общество кардиологов (ВНОК). Национальные рекомендации по диагностике и лечению артериальной гипертонии. М., 2004г.The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Guidelines on the management of stable angina pectoris: executive summary. Eur Heart J 2006;27: 1341-1381.The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Guidelines on the management of stable angina pectoris: executive summary. Eur Heart J 2006;27: 1341-1381.Комитет экспертов ВНОК. Диагностика и лечение ста бильной стенокардии. Российские рекомендации. Кардиоваскулярная терапия и профилактика, 2004г., приложение.Комитет экспертов ВНОК. Диагностика и лечение ста бильной стенокардии. Российские рекомендации. Кардиоваскулярная терапия и профилактика, 2004г., приложение.Dagenais, G.R., Pogue J., Fox K. et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006: 368: 581-588.Dagenais, G.R., Pogue J., Fox K. et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006: 368: 581-588.S. D. Solomon, M. M. Rice, k. A. Jablonski, et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the prevention of events with ACE inhibition (PEACE) trial. Circulation 2006: 114; 26-31.S. D. Solomon, M. M. Rice, k. A. Jablonski, et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the prevention of events with ACE inhibition (PEACE) trial. Circulation 2006: 114; 26-31.Rehngvist N., Hjemdahl P., Billing E. et al. Effects of metroprolol vs verapamil in patients with stable angina pectoris. Eur Heart J 1996: 17:76-81.Rehngvist N., Hjemdahl P., Billing E. et al. Effects of metroprolol vs verapamil in patients with stable angina pectoris. Eur Heart J 1996: 17:76-81.O'Leary D.H., Polak J.F., Kronmal R.A., et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340: 14-22.O'Leary D.H., Polak J.F., Kronmal R.A., et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340: 14-22.A. Zanchetti, E. A. Rosei, C. D. Palu, et al. The verapamil in hypertension and atherosclerosis study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998, 16: 1667-1676.A. Zanchetti, E. A. Rosei, C. D. Palu, et al. The verapamil in hypertension and atherosclerosis study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998, 16: 1667-1676.Brown M.J., Palmer C.R., Castaigne A., et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: INSIGHT. Lancet 2000; 356: 366-372.Brown M.J., Palmer C.R., Castaigne A., et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: INSIGHT. Lancet 2000; 356: 366-372.Zanchetti A., Bond G., Hennig M., et al. Calcium antagonist lacidipine slows down progression asymptomatic carotid atherosclerosis. Principal results of the European lacidipine study on atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 2422-2427.Zanchetti A., Bond G., Hennig M., et al. Calcium antagonist lacidipine slows down progression asymptomatic carotid atherosclerosis. Principal results of the European lacidipine study on atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 2422-2427.Zanchetti A. The antiatherogenic effects of antihypertensive treatment: trials completed and ongoing. Curr Hypertens Rep 2001: 3: 350-359.Zanchetti A. The antiatherogenic effects of antihypertensive treatment: trials completed and ongoing. Curr Hypertens Rep 2001: 3: 350-359.ФранцияФранцияPepine C., Handberg E.M., Cooper-deHoff R.M., et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-2816.Pepine C., Handberg E.M., Cooper-deHoff R.M., et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-2816.Johan D. Lefrandt, Jorg Heitmann, Knut Sevre, et al. Contrasting effects of verapamil and amlodipine on cardiovascular stress responses in hypertension. Blackwell Science Ltd Br J Clin Pharmacol 2001; 52:687-692.Johan D. Lefrandt, Jorg Heitmann, Knut Sevre, et al. Contrasting effects of verapamil and amlodipine on cardiovascular stress responses in hypertension. Blackwell Science Ltd Br J Clin Pharmacol 2001; 52:687-692.Ruggenenti P., Fassi A., Ilieva A.P., et al for the BENEDICT investigators. Preventing Microalbuminuria in type 2 diabetes: the BENEDICT study results. N Engl J Med 2004: 351; 1941-1951.Ruggenenti P., Fassi A., Ilieva A.P., et al for the BENEDICT investigators. Preventing Microalbuminuria in type 2 diabetes: the BENEDICT study results. N Engl J Med 2004: 351; 1941-1951.Hansson L., Lindholm L., Ekbom T., et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular morbidity and mortality the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:1751-1756Hansson L., Lindholm L., Ekbom T., et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular morbidity and mortality the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:1751-1756Hansson L., Hedner T., Lund-Johansen P., et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-365.Hansson L., Hedner T., Lund-Johansen P., et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-365.The ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker vs diuretic (ALLHAT). JAMA 2002; 288: 2981-2997The ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker vs diuretic (ALLHAT). JAMA 2002; 288: 2981-2997Sever P.S., Dahlof B., Poulter N.R, et al, for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906.Sever P.S., Dahlof B., Poulter N.R, et al, for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906.
The authors declare that there are no conflicts of interest present.